


## Levobunolol

Cat. No.:	HY-B1035A
CAS No.:	47141-42-4
Molecular Formula:	C <sub>17</sub> H <sub>25</sub> NO <sub>3</sub>
Molecular Weight:	291.39
Target:	Adrenergic Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

**Description** Levobunolol (l-Bunolol) is a potent and nonselective  $\beta$ -adrenergic receptor antagonist. Levobunolol is an ocular hypotensive agent and lowers mean intraocular pressure (IOP). Levobunolol can be used for glaucoma and superior oblique myokymia (SOM) research<sup>[1][2][3]</sup>.

**IC<sub>50</sub> & Target**  $\beta$  adrenergic receptor

### CUSTOMER VALIDATION

- BMC Ophthalmol. 2021 Dec 5;21(1):419.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

- [1]. Mohammadi M, et al. Injectable drug depot engineered to release multiple ophthalmic therapeutic agents with precise time profiles for postoperative treatment following ocular surgery. *Acta Biomater.* 2018 Jun;73:90-102.
- [2]. Kumar, N, et al. Extended levobunolol release from Eudragit nanoparticle-laden contact lenses for glaucoma therapy. *Futur J Pharm Sci* 6, 109 (2020).
- [3]. Zhang M, et al. Superior oblique myokymia treated with levobunolol. *J AAPOS.* 2018 Feb;22(1):67-69.e2.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA